

[IDT expands coronavirus line, partners with Sherlock](#)

written by CAP TODAY
September 18, 2020

September 2020—Integrated DNA Technologies and Sherlock Biosciences have entered into a strategic collaboration to enable large-scale manufacturing of the Sherlock CRISPR SARS-CoV-2 kit for the detection of COVID-19. IDT will supply several components, including the Cas13a enzyme, on which the test is based, as well as a CRISPR RNA and primer mix.



©2026 CAP TODAY, all rights reserved.

[Qiagen expands coronavirus NGS, software solutions](#)

written by CAP TODAY
September 18, 2020

September 2020—Qiagen has launched the QIAseq SARS-CoV-2 Primer Panel for next-generation sequencing of the novel coronavirus genome and integrated analysis and interpretation workflows for insights into the evolution and spread of the virus.



©2026 CAP TODAY, all rights reserved.

[Abbott's 15-minute COVID-19 antigen test gets EUA](#)

written by CAP TODAY
September 18, 2020

September 2020—The FDA has issued emergency use authorization for Abbott's BinaxNow COVID-19 Ag Card rapid test for the detection of COVID-19 infection.



©2026 CAP TODAY, all rights reserved.

[Vidas SARS-CoV-2 antibody serology tests get EUA](#)

written by CAP TODAY
September 18, 2020

September 2020—BioMérieux received emergency use authorization by the FDA for its Vidas SARS-CoV-2 IgM and Vidas SARS-CoV-2 IgG serology tests.



©2026 CAP TODAY, all rights reserved.

[Compass points chart the pandemic](#)

written by CAP TODAY
September 18, 2020

September 2020—Between a rock and a hard place. Trying to stay ahead, trying to build inventory. Chasing multiple new testing requests. Anticipating influenza. That’s where laboratory leaders said their labs were in early August when CAP TODAY publisher Bob McGonnagle convened members of the Compass Group on Zoom to share their pandemic experiences. They shared surprise, too, that the situation is what it is: “Not a clue in my mind that this would go past the springtime,” said Stan Schofield, president of NorDx and senior VP, MaineHealth. McGonnagle asked them about the diversion of supplies, the coming flu season, IT support, lessons and long-term changes, and more.

See current issue below for additional COVID-19 coverage or access all COVID-19 articles [here](#).



©2026 CAP TODAY, all rights reserved.

[Real-time QC: on course for prime time?](#)

written by CAP TODAY
September 18, 2020

September 2020—Bill Gates was just 10 years old and the Beatles were still playing live concerts when the concept of patient-based real-time quality control was proposed in 1965. At the time, patient-based real-time QC (PBRTQC) was based on the “average of normals,” a precursor of moving averages.



©2026 CAP TODAY, all rights reserved.

[Oh, the places you'll go when flu season hits](#)

written by CAP TODAY
September 18, 2020

September 2020—The twinned challenge of testing for SARS-CoV-2 and the upcoming influenza season has a bit of *The Cat in the Hat* energy running through it. How does one manage to keep Thing One and Thing Two from creating unmitigated chaos? Maybe one doesn't, not completely. A pandemic-based flu season will by its very nature be protean.



©2026 CAP TODAY, all rights reserved.

[What's new in latest transfusion medicine checklist](#)

written by CAP TODAY
September 18, 2020

September 2020—Strong quality management, patient safety, and conformity with regulations are at the heart of the new and revised requirements in the 2020 CAP accreditation program transfusion medicine checklist, released in June.



©2026 CAP TODAY, all rights reserved.

Juan Rosai, ‘master of the neoplastic universe’

written by CAP TODAY
September 18, 2020

September 2020—Great mentors, once passed, live on in the ideas, memories, and dreams of their students. For those like me, lucky enough to have been a student of Juan Rosai, MD, and to have heard him speak, the experience will never be forgotten.



©2026 CAP TODAY, all rights reserved.

Why do universal HRD testing in ovarian cancer?

written by CAP TODAY
September 18, 2020

September 2020—Genetic testing in ovarian cancer has a therapeutic implication that will aid in developing a treatment plan, and it is pathologists who should take the lead in creating the testing protocol, said Samuel Caughron, MD, pathologist, president, and CEO of MAWD Pathology Group, in a recent CAP TODAY webinar. Dr. Caughron explained the rationale for universal homologous recombination deficiency testing in patients with advanced ovarian cancer. The webinar, made possible by a medical sponsorship from AstraZeneca, is at www.captodayonline.com.



©2026 CAP TODAY, all rights reserved.